# Par Formulations Private Limited – FDA 483, Jun 25, 2026

Source: https://www.keypedia.com/records/483/par-formulations-private-limited/8cf3d3bf-3fff-446e-9b43-67864cd0bfc6

> FDA 483 for Par Formulations Private Limited on June 25, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Par Formulations Private Limited
- Inspection Date: 2026-06-25
- Product Type: drugs
- Office Name: Office of Partnerships
- Summary: An FDA inspection of Par Formulations Private Limited in Indore, India, a drug manufacturer, revealed two significant observations. The firm failed to perform routine equipment calibration according to a written program, specifically before dismantling and relocating equipment. Additionally, containers and closures were not tested for conformance with written procedures, as records for primary drug product label verification did not document the specific approved artwork used.

## Related Documents

- [483 - 2024-03-26](https://www.keypedia.com/records/483/par-formulations-private-limited/fb303e13-24ca-4032-a171-13e6cc9963cb) — date: March 26, 2024
- [483 - 2022-04-05](https://www.keypedia.com/records/483/par-formulations-private-limited/400bbc4f-1742-4da7-8c2c-262920e13ee5) — date: April 5, 2022

## Related Officers

- [Consumer Safety Officer](https://www.keypedia.com/people/jeffrey-p-raimondi/7576ca4e-d9e8-4015-9ae6-9498e76058d3)

Company: https://www.keypedia.com/companies/par-formulations-private-limited/5f554b68-cd43-4880-b22b-fca02aab50f0

Office: https://www.keypedia.com/offices/office-of-partnerships/83acc701-fc5a-4876-bb34-7499e31541d3